Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals

Ajlan AM, Ahyad RA, Jamjoom LG, Alharthy A, Madani TA (2014) Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. AJR Am J Roentgenol 203(4):782–787

PubMed  Article  Google Scholar 

Ali RM, Ghonimy MB (2021) Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients. Egypt J Radiol Nucl Med 52(1):1–8

Article  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI (2021) Acute kidney injury and COVID-19. Egypt J Intern Med 33(1):1–5

Article  Google Scholar 

Al-Kuraishy HM, Al-Naimi MS, Lungnier CM, Al-Gareeb AI (2020a) Macrolides and COVID-19: an optimum premise. Biomed Biotechnol Res J 4(3):189

Article  Google Scholar 

Al-Kuraishy HM, Al-Niemi MS, Hussain NR, Al-Gareeb AI, Al-Harchan NA, Al-Kurashi AH (2020b) The Potential Role of Renin Angiotensin System (RAS) and Dipeptidyl Peptidase-4 (DPP-4) in COVID-19: Navigating the Uncharted. In: Kibel A (ed) Selected chapters from the reninangiotensin system. IntechOpen, London, pp 151–165

Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Alblihed M, Cruz-Martins N, Batiha GE (2021a) COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type II diabetes mellitus: the anti-inflammatory role of metformin. Front Med 8:110

Article  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Faidah H, Al-Maiahy TJ, Cruz-Martins N, Batiha GE (2021b) The looming effects of estrogen in Covid-19: a rocky rollout. Front Nutr 8:649128

PubMed  PubMed Central  Article  CAS  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Qusty N, Cruz-Martins N, Batiha GE (2021c) Sequential doxycycline and colchicine combination therapy in Covid-19: the salutary effects. Pulm Pharmacol Ther 67:102008

CAS  PubMed  PubMed Central  Article  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Alkazmi L, Habotta OA, Batiha GE (2022) High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons. Inflammopharmacology 26:1

Google Scholar 

Al-kuraishy H, Al-Gareeb AI, Guerreiro SG, Cruz-Martins N, Batiha GE (2021d) COVID-19 in relation to hyperglycemia and diabetes mellitus. Front Cardiovasc Med 8:335

Google Scholar 

Amarelle L, Quintela L, Hurtado J, Malacrida L (2021) Hyperoxia and lungs: what we have learned from animal models. Front Med 8:235

Article  Google Scholar 

Aravamudhan A, Haak AJ, Choi KM, Meridew JA, Caporarello N, Jones DL, Tan Q, Ligresti G, Tschumperlin DJ (2020) TBK1 regulates YAP/TAZ and fibrogenic fibroblast activation. Am J Physiol Lung Cell Mol Physiol 318(5):L852–L863

CAS  PubMed  PubMed Central  Article  Google Scholar 

Artigas L, Coma M, Matos-Filipe P, Aguirre-Plans J, Farrés J, Valls R, Fernandez-Fuentes N, de la Haba-Rodriguez J, Olvera A, Barbera J, Morales R (2020) In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS One 15(10):e0240149

CAS  PubMed  PubMed Central  Article  Google Scholar 

Balaramnavar VM, Ahmad K, Saeed M, Ahmad I, Kamal M, Jawed T (2020) Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 Mpro. RSC Adv 10(66):40264–40275

CAS  PubMed  PubMed Central  Article  Google Scholar 

Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, Daßler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M (2020) Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med 217(6): e20200652

CAS  PubMed  PubMed Central  Article  Google Scholar 

Boopathy GT, Hong W (2019) Role of hippo pathway-YAP/TAZ signaling in angiogenesis. Front Cell Dev Biol 7:49

PubMed  PubMed Central  Article  Google Scholar 

Bridevaux PO, Aubert JD, Soccal PM, Mazza-Stalder J, Berutto C, Rochat T, Turin L, Van Belle S, Nicod L, Meylan P, Wagner G (2014) Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax 69(1):32–38

PubMed  Article  Google Scholar 

Carter NJ (2011) Pirfenidone Drugs 71(13):1721–1732

CAS  PubMed  Article  Google Scholar 

Chen Y, Zhao X, Sun J, Su W, Zhang L, Li Y, Liu Y, Zhang L, Lu Y, Shan H, Liang H (2019) YAP1/twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF. Cell Death Differ 26(9):1832–1844

CAS  PubMed  PubMed Central  Article  Google Scholar 

Co JL, Badilles FA, Halun CB, Dy-Agra GN, Campomanes CM, Pagcatipunan RS, Divinagracia RM (2022) Pirfenidone for COVID-19 Associated Pulmonary Fibrosis: A Case Series. InC38. RARE AND COMMON ILDS: EPIDEMIOLOGY, DIAGNOSIS, AND MANAGEMENT 2022 May (pp. A4046-A4046). American Thoracic Society.

Combet M, Pavot A, Savale L, Humbert M, Monnet X (2020) Rapid onset honeycombing fibrosis in spontaneously breathing patient with Covid-19. Eur Respir J 56(2):2001808

CAS  PubMed  PubMed Central  Article  Google Scholar 

Das KM, Lee EY, Singh R, Enani MA, Al Dossari K, Van Gorkom K, Larsson SG, Langer RD (2017) Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging 27(3):342

PubMed  PubMed Central  Article  Google Scholar 

Denney L, Branchett W, Gregory LG, Oliver RA, Lloyd CM (2018) Epithelial-derived TGF-β1 acts as a pro-viral factor in the lung during influenza A infection. Mucosal Immunol 11(2):523–535

CAS  PubMed  Article  Google Scholar 

Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A (2020) The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2. Eur J Clin Pharmacol 76(11):1615–1618

CAS  PubMed  PubMed Central  Article  Google Scholar 

Fila E, Rocco I, Rocco G, Zuccon U, Ruberti E (2021) Recommendations for the respiratory rehabilitation of hospitalized and discharged COVID-19 patients: a sistematic review. G Ital Med Lav Erg 43(1):56–65

Google Scholar 

Goda C, Balli D, Black M, Milewski D, Le T, Ustiyan V, Ren X, Kalinichenko VV, Kalin TV (2020) Loss of FOXM1 in macrophages promotes pulmonary fibrosis by activating p38 MAPK signaling pathway. PLoS Genet 16(4):e1008692

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gokey JJ, Sridharan A, Xu Y, Green J, Carraro G, Stripp BR, Perl AK, Whitsett JA (2018) Active epithelial Hippo signaling in idiopathic pulmonary fibrosis. JCI Insight 3(6):e98738

PubMed Central  Article  Google Scholar 

Grillo F, Barisione E, Ball L, Mastracci L, Fiocca R (2021) Lung fibrosis: an undervalued finding in COVID-19 pathological series. Lancet Infect Dis 21(4):e72

CAS  PubMed  Article  Google Scholar 

Grimes JM, Grimes KV (2020) p38 MAPK inhibition: a promising therapeutic approach for COVID-19. J Mol Cell Cardiol 144:63–65

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gu Y, Cao J, Zhang X, Gao H, Wang Y, Wang J, Zhang J, Shen G, Jiang X, Yang J, Zheng X (2020) Interaction network of SARS-CoV-2 with host receptome through spike protein. https://doi.org/10.1101/2020.09.09.287508

Haak AJ, Kostallari E, Sicard D, Ligresti G, Choi KM, Caporarello N, Jones DL, Tan Q, Meridew J, Espinosa AM, Aravamudhan A (2019) Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis. Sci Transl Med 11(516):eaau6296

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hamer M, Kivimäki M, Gale CR, Batty GD (2020) Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: a community-based cohort study of 387,109 adults in UK. Brain Behav Immun 87:184–187

CAS  PubMed  PubMed Central  Article  Google Scholar 

Johansson PI, Bestle M, Søe-Jensen P, Kristiansen KT, Stensballe J, Clausen NE, Perner A (2020) The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 21:746

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kai H, Kai M (2020) Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res 43:648–654

CAS  PubMed  PubMed Central  Article  Google Scholar 

Karamian A, Paktinat S, Esfandyari S, Nazarian H, Ziai SA, Zarnani AH, Salehpour S, Hosseinirad H, Karamian A, Novin MG (2021) Pyrvinium pamoate induces in-vitro suppression of IL-6 and IL-8 produced by human endometriotic stromal cells. Hum Exp Toxicol 40(4):649–660

CAS  PubMed  Article  Google Scholar 

Kayarat B, Khanna P, Sarkar S (2021) Pulmonary fibrosis in COVID-19 recovered patients: problem and potential management. Indian J Crit Care Med 25(2):242–244

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kayhan S, Kocakoç E (2020) Pulmonary fibrosis due to COVID-19 pneumonia. Korean J Radiol 21(11):1273

PubMed  PubMed Central  Article  Google Scholar 

Konigshoff M, Wilhelm A, Jahn A, Sedding D, Amarie OV, Eul B, Seeger W, Fink L, Gunther A, Eickelberg O, Rose F (2007) The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis. Am J Respir Cell Mol Biol 37(6):640–650

PubMed  Article  CAS  Google Scholar 

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U (2017) Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev 26(146):170057

PubMed  Article  Google Scholar 

Latella G, Viscido A (2020) Could pirfenidone also be effective in treating intestinal fibrosis? Cells 9(8):1762

PubMed Central  Article  Google Scholar 

Lee JH, Lim CM, Koh Y, Hong SB, Song JW, Huh JW (2020) High-flow nasal cannula oxygen therapy in idiopathic pulmonary fibrosis patients with respiratory failure. J Thorac Dis 12(3):966

PubMed

留言 (0)

沒有登入
gif